Quick Biology

Executive Summary

Quick Biology is a US-based provider of genomic services and molecular biology solutions, operating at the intersection of genetics, genomics, and diagnostics. Founded in 2010 and headquartered in San Diego, the company enables research and clinical testing through tools and services that accelerate scientific discovery. With a focus on accelerating genomic analysis, Quick Biology supports a range of applications from basic research to diagnostic development. The market for genomic services is expanding rapidly, driven by increasing adoption of precision medicine and next-generation sequencing (NGS) in oncology, rare disease, and reproductive health. Quick Biology is well-positioned to capture growth by offering scalable, high-quality services to academic, pharmaceutical, and clinical customers. The company's competitive advantage lies in its integrated service model and technical expertise, though it faces competition from larger genomics suppliers and diagnostic labs. To sustain growth, Quick Biology must innovate its service menu, expand its customer base, and potentially develop proprietary diagnostic tests. The outlook is positive given the tailwinds in genomics, but visibility into near-term financial performance is limited. Key risks include pricing pressure, regulatory changes, and the need for continuous investment in technology.

Upcoming Catalysts (preview)

• Q3 2026Launch of new NGS-based oncology panel for liquid biopsy70% success
• Q3 2026Strategic partnership with a top-20 pharmaceutical company for clinical trial genomic services50% success
• Q4 2026Introduction of a direct-to-consumer genetic testing service30% success